Status:
UNKNOWN
Hypersplenism in Patients With Liver Cirrhosis and Portal Hypertension
Lead Sponsor:
Assiut University
Conditions:
Hypersplenism
Eligibility:
All Genders
18-70 years
Brief Summary
The spleen could be considered a neglected organ. To date, it has been deemed an ancillary organ in portal hypertension or an organ localization in lymphoproliferative diseases. Hypersplenism is a com...
Detailed Description
Hypersplenism is a clinical syndrome characterized by: (1) Splenomegaly (2) Pancytopenia or a reduction in the number of one or more types of blood cells (3) Normal production or hyperplasia of the pr...
Eligibility Criteria
Inclusion
- All patients with documented evidence of liver cirrhosis (of any etiology other than alcoholic cirrhosis) and portal hypertension, based on clinical examination, abdominal ultrasound examination, upper gastrointestinal endoscopy.
- Male and female patients aged between 18-60 years.
Exclusion
- Patients with splenomegaly of any cause other than liver cirrhosis.
- Patients with any lymphoproliferative disorders.
- Patients with extrahepatic malignancy.
- Patients younger than 18 years old.
- Any associated cardiovascular disease.
- Failure to obtain consent.
Key Trial Info
Start Date :
September 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2018
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT03269877
Start Date
September 1 2017
End Date
December 31 2018
Last Update
September 1 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.